2. Protein Tyrosine Kinase/RTK
  3. c-Fms
  4. Cabiralizumab

Cabiralizumab  (Synonyms: 卡比利珠单抗; FPA 008; Anti-Human CSF1R Recombinant Antibody)

目录号: HY-P99259 纯度: 99.73%
COA 技术支持

Cabiralizumab (FPA 008) 是一种抗 CSF1R 单克隆抗体 (MAb)。Cabiralizumab 可增强 T 细胞浸润和抗肿瘤 T 细胞免疫反应。Cabiralizumab 抑制破骨细胞的活化并阻止骨质破坏，可用于类风湿性关节炎 (RA) 的研究。Cabiralizumab 可与 Nivolumab (HY-P9903) 结合用于肺癌研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

CAS No. : 1613144-80-1

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥2800
In-stock
5 mg ￥7200
In-stock
10 mg ￥11500
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Cabiralizumab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research[1][2][3][4].

同型

Human IgG4 kappa
推荐同型对照抗体
反应种属

Human
IC50 & Target

CSF1R/M-CSFR/CD115
体外研究
(In Vitro)

Cabiralizumab (7 天) 在体外培养的胰腺导管腺癌 (PDAC) 的门静脉血单核细胞 (PortalBMC) 未分类样本中可破坏循环肿瘤细胞 (CTC) 簇形成，并增加 CTC 凋亡[4]。
Cabiralizumab (7 天) 在体外培养的 PDAC 的 PortalBMC 中可重新激活 T 细胞 (CD3+CD25+CTLA4-PD1L1-) 并增加的 IFNγ 产生[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cabiralizumab 相关抗体:
体内研究
(In Vivo)

Cabiralizumab (200-400 μg；腹腔注射；每周两次，共 5 次) (αCSF1R) 具有抗肿瘤活性，其在小鼠模型中高剂量效果不如低剂量3.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57Bl6 male mice model (YUMMER1.7 (UV irradiated derivative of YUMM1.7 carrying a higher number of somatic mutations) or YUMM1.7 (BrafV600E /Pten−/−, Cdkn2a−/−) cells were subcutaneously injected into the left flank) (8-9 week old)[3]
Dosage: 200, 400 μg
Administration: Intraperitoneal injection (i.p.); twice a week for 5 times
Result: In the group treated with higher dose αCSF1R, 55% of mice (11/20) reached endpoint, whereas mice treated with lower dose αCSF1R fared better with 25% (5/20) reaching the endpoint in YUMMER1.7 mice model.
Lower αCSF1R dose resulted in improved survival compared to the higher αCSF1R dose in YUMMER1.7 mice model.
Treatment with both lower and higher anti-CSF1R dose delayed the tumor growth, but all tumors eventually grew out to endpoint in YUMM1.7 mice model.
Clinical Trial
基因 ID

1436  [NCBI]

Accession
应用

ELISA, FACS, Functional assay
偶联物

Unconjugated
复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.
分子量

146.02 kDa

CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

卡比利珠单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Immobilized Human M-CSFR/CSF1R Protein can bind Cabiralizumab. The EC50 for this effect is 2.465 ng/mL.
纯度 & 产品资料
参考文献

Cabiralizumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cabiralizumab1613144-80-1FPA 008 Anti-Human CSF1R Recombinant Antibody卡比利珠单抗FPA008FPA-008c-FmsCSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RT cellarthritisRAlung cancerimmune responsetumorInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Cabiralizumab
目录号：
HY-P99259
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z